FierceBiotech

I-Mab lays off 27% of workforce after pivoting to CLDN18.2 bispecific

I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...
FierceBiotech

I-Mab pauses Sanofi-partnered prospect to make play for busy CLDN18.2 space

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has put ...
Seeking Alpha

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

Good day, and welcome to the I-Mab Business Update Call. [Operator Instructions]. As a reminder, this conference call is being recorded and will be available for replay on the company's website. I ...
Nasdaq

I-Mab Completes Enrollment Ahead of Schedule in First Dose Expansion Cohort of Givastomig Study, Doses First Patient in Second Cohort

I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...
Hosted on MSN

I-Mab to Vote on Name Change to NovaBridge Biosciences

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I-MAB ( (IMAB)) just unveiled an ...